Hi-Tech Pharmacal 8-K 2010
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported) March 12, 2010
HI-TECH PHARMACAL CO., INC.
(Exact Name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction of Incorporation)
(Registrants Telephone Number, Including Area Code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
An annual meeting of security holders was held on November 12, 2009. The Company solicited proxies and shares were present in person and by proxy. The proposals are described in detail in the Companys definitive proxy statement filed with the Securities and Exchange Commission on October 1, 2009.
Set forth is the number of votes cast for, against or withheld as to each item voted upon.
(ii) Adoption of the Companys 2009 Stock Option Plan for a fifteen (15) year term and authorization of 500,000 shares of Common Stock reserved for issuance thereunder.
(iii) Ratification of the appointment of Eisner LLP as the Companys independent auditors for the fiscal year ending April 30, 2011.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.